Feedback / Questions
coltuximab ravtansine (SAR3419) - ImmunoGen
ImmunoGen: Corporate Presentation
(Immunogen)
-
Feb 12, 2016 -
Anticipated initiation of P2 trial in combination regimen for DLBCL in H2 2016
Anticipated new P2 trial
•
Hematological Malignancies • Non-Hodgkin's Lymphoma • Oncology
http://files.shareholder.com/downloads/ABEA-5VU3S1/1429195558x0x874164/C3C74A11-0CB1-4663-9ED3-DECEEE551A3E/ImmunoGen_corp_pres_as_of_2-10-16_for_website.pdf
Feb 12, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.